← Back to all careers

Senior Scientist, Ligand Discovery

Introduction

Enara Bio™ is a science-led company leveraging its proprietary discovery platforms to deliver targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel, shared immunotherapy targets such as Dark Antigens™ and HLA-independent ligands. We are pioneering approaches to exploit these targets with a TCR-directed T-cell immunotherapy product pipeline.

Enara Bio was founded in 2016 and has been well funded to invest in the build out and growth of our R&D efforts and our fantastic team. The company is based in Oxford, UK.

Job Summary

We want you to help to build an understanding of how metabolic pathways in tumours shape the expression of metabolites that may be targets for Enara Bio's tumour-specific T cell receptors and support the Ligand Discovery Team with your knowledge to help identify and validate novel targets. This is an opportunity for an innovative scientist to be a key part of a team striving to develop novel, impactful TCR therapies for cancer patients.

As a Senior Scientist you will be a key part of a team working on several high impact areas of research within the Ligand Discovery team to identify and characterise targets for T cell receptors. This data will drive the development of biologics and cell therapies to make a meaningful difference for patients suffering from cancer.

You will be expected to:

We are a TCR discovery company focused on dark antigens, which are classical HLA peptide targets and novel MR-1 associated metabolite targets. We are looking for a target identification and validation Senior Scientist with a background in tumour metabolism to explore metabolites and metabolic pathways that are present in cancer cells. Most cancer cells undergo metabolic reprogramming and have dysregulated metabolic activity that differentiates them from normal tissues.

Key Responsibilities

  • Designing conducting and evaluating experiments using gene editing tools and technologies to validate metabolic pathway biology
  • Developing and utilising pharmacological cell-based or biochemical screening assay platforms.
  • Working closely with other research functional teams (e.g., Bioinformatics, Metabolomics and Immunopeptidomics) to validate the role of novel T cell antigens and cognate T cell receptors in cancer. This work will form the basis of T cell therapies for cancer
  • T cell profiling for very low frequency cells (use of Elispot, multimers), FACS sorting/analysis, CTL cloning, cytokine production (ELISA/TR-FRET) and recombinant T cell receptor expression/characterization.
  • Killing assays using flow and electrical impedance-based methodology.

Minimum Qualifications and Experience required

  • Proven experience of working with gene editing techniques in a biotech or academic setting (minimum of 3 years)
  • A PhD in a relevant scientific discipline, expertise with T-cell immunology preferred.
  • Proven experience of developing pharmacological cell-based or biochemical screening platforms and cancer metabolism desirable
  • Experience of managing and mentoring other scientists

Closing date

Until filled

Further information

The Enara Bio team is driven to make a meaningful difference for people affected by cancer. Our culture is defined by our behavioural ethos:
  • Act with unconditional positive regard and integrity
  • Support each other to grow and develop
  • Promote a collaborative, passionate and fun working environment
  • Innovate by discussing issues, data, and ideas openly
  • Respect each other and value our diversity
  • Embrace our shared goals and take ownership of our journey

We offer a competitive salary, commensurate with qualifications and experience, and a benefits package including pension and health insurance.

Applicants should be able to demonstrate proof of the right to work in United Kingdom. Enara Bio Limited is an equal opportunities employer.

Apply for this role

Job Reference: 553855